Drug interactions
Capecitabine + Ublituximab
Severity: Moderate
Capecitabine and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ublituximab depletes B cells and capecitabine causes myelosuppression, so together they may increase the risk of infection. The effect is additive and is mostly relevant in patients with already compromised immunity.
What this interaction means in plain words
Capecitabine and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Capecitabine belongs to Oncology; Ublituximab belongs to Miscellaneous.
Why it happens
Additive immunosuppression from anti-CD20 B-cell depletion and cytotoxic bone marrow suppression.
What to do
Monitor for signs of infection and check blood counts regularly during combined treatment. Consider the duration of B-cell depletion when planning chemotherapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Capecitabine and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Capecitabine
Other interactions of Ublituximab
Frequently asked questions
Can I take Capecitabine with Ublituximab?
MediHelp rates the interaction as moderate. Capecitabine and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ublituximab depletes B cells and capecitabine causes myelosuppression, so together they may increase the risk of infection. The effect is additive and is mostly relevant in patients with already compromised immunity.
How serious is the interaction between Capecitabine and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for signs of infection and check blood counts regularly during combined treatment. Consider the duration of B-cell depletion when planning chemotherapy.
What other medicines interact with Capecitabine?
MediHelp also lists interactions of Capecitabine with, for example, Adenovirus types 4 and 7 live, Arsenic trioxide, Axicabtagene ciloleucel. The full list is on the Capecitabine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
